Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

CHENGDU, China, April 24, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE)…